# A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

> **NCT06545500** · PHASE2 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 46 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Glycopyrrolate (85 μg)
- **DRUG:** Glycopyrrolate (42.5 μg)
- **DRUG:** Glycopyrrolate (14 μg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06545500
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-16
- **Primary completion:** 2025-01-02
- **Final completion:** 2025-01-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06545500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06545500, "A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06545500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*